←
Fabrice Lucien, PhD990 posts
Fabrice Lucien, PhD avatar

Fabrice Lucien, PhD

@flscientist

🇫🇷🇨🇦🇺🇸 Associate Professor of Urology & Immunology - Mayo Clinic - Basic and Translational Research - Liquid biopsies and next-gen cancer immunotherapies

◷ Joined December 2016▧ 117 Photos and videos
Joe Biden avatar
⟳ Fabrice Lucien, PhD retweeted
Joe Biden@JoeBiden·Nov 12

Today the American Cancer Society made important changes to their prostate cancer screening guidelines: Men 50 to 69 should get a PSA test every two years; Black men and men with a family history of prostate cancer should get one every year starting at 45; and starting at age 70, men should talk to their doctors about what's right to them. I know firsthand the toll of this disease, and I know that catching it early saves lives. So talk to your doctor, get screened, and let’s keep working to end cancer as we know it.

As rates of advanced prostate cancer continue to rise, the American Cancer Society is recommending that most men ages 50 to 69 get screened every other year. nbcnews.com/health/cancer/ne…

Haidong Dong avatar
⟳ Fabrice Lucien, PhD retweeted
Haidong Dong@hd_DongMDPhD·Oct 16

Our newly published theoretical mathematical model of T-cell responses to PD-1 therapy, developed from more than a decade of clinical observations, offers new insights into the mechanisms and dynamics underlying cancer immunotherapy. | Science Advances science.org/doi/10.1126/scia…

Amar Kishan avatar
⟳ Fabrice Lucien, PhD retweeted
Amar Kishan@AmarUKishan·Oct 13

Updated LUNAR analysis out in @EUplatinum. Now with a median follow-up of 32 months, exploratory analyses confirm the addition of 177Lu-PNT2002 to SBRT improves polymetastatic PFS (6 or more new lesion), castrate disease-free survival, and CT-based PFS (i.e., conventional MFS) authors.elsevier.com/sd/arti…

Haidong Dong avatar
⟳ Fabrice Lucien, PhD retweeted
Haidong Dong@hd_DongMDPhD·Sep 9

After 15 years of our discovery of soluble PD-L1(B7-H1), we finally have a proof of it as a therapeutic target and have a way to specifically remove it in vivo to restore antitumor immunity. businesswire.com/news/home/2…

Fabrice Lucien, PhD avatar
Fabrice Lucien, PhD@flscientist·Sep 28

Looking forward to sharing our progress on EV-based liquid biopsy and learning more on how to integrate computational biology in our work @iscb Great Plains.

Post attachment
Fabrice Lucien, PhD avatar
Fabrice Lucien, PhD@flscientist·Sep 8

Tunneling NanoTubes (TNT) as an effective means for intercellular mRNA transfer in neighboring cells. Much more efficient than EV-mediated transfer. cell.com/cell-reports/fullte…

Fabrice Lucien, PhD avatar
Fabrice Lucien, PhD@flscientist·Aug 31

ALWAYS validate your reagents with proper controls and don’t trust product sheets or prior publications. When you see how much cost antibodies nowadays ($500+/100 micrograms), that’s shocking but unfortunately not surprising. reeserichardson.blog/2026/08… nature.com/articles/d41586-0…

Katy Beckermann avatar
⟳ Fabrice Lucien, PhD retweeted
Katy Beckermann@katy_beckermann·Jul 16

Closing the night on prostate. From high risk localized disease discussion of best treatment options surgery vs radiation... To the mHSPC question that keeps coming up: who do you intensify, and who can you spare? Biomarkers are starting to answer it. 🎯 #GURounds expertly led by @KSchaffer17 with input from the entire Nashville team @BGarmezy @alantanmd @TomJayram @AKRadDoc @DavidMorrismd Representation from @VUMCRadOnc @TNOncology @theGHCR @SarahCannonDocs

Post attachment
Yalda Nikanpour avatar
⟳ Fabrice Lucien, PhD retweeted
Yalda Nikanpour@YaldaNikanpour·Jul 4

Our new paper is out! 🎉 In mCRPC treated with PSMA-RLT, metastatic disease volume emerged as a key driver of outcomes. A simple stratification that could sharpen how we select patients. Full study 🔗 link.springer.com/article/10… @JackAndrewsMD @MayoRadiology @MayoUrology

Fabrice Lucien, PhD avatar
Fabrice Lucien, PhD@flscientist·May 22

Exciting work on EV-based biomarkers in advanced prostate cancer treated with Lu-177 PSMA, spearheaded by @AJangMD @MayoCancerCare @MayoUrology

Ab#5068 @ASCO #ASCO26 by @AJangMD👉 bit.ly/4dB4bNx👉Plasma-derived extracellular vesicles (EVs) in 123 pts w/ mPC treated w/ Lu-177 #prostatecancer➡️CEACAM5 + TROP2 EV composite best predicted PSA50 response (OR 2.96)👇 @flscientist @oncoalert @urotoday @PCF_science

Post attachmentPost attachment
Mayo Clinic Urology avatar
⟳ Fabrice Lucien, PhD retweeted
Mayo Clinic Urology@MayoUrology·May 20

Mayo Clinic Urology was honored to host visiting professor Dr. Hashim Ahmed for a discussion on advances in prostate cancer screening, precision diagnosis, and focal therapy. #ProstateCancer #FocalTherapy @imperialcollege @LondonProstate1 @SBoorjian @DerekLomas

Post attachment

We are excited to welcome Dr. Hashim U. Ahmed to @MayoClinic as the upcoming James H. DeWeerd Visiting Professorship in Urology in Rochester, MN! @LondonProstate1 @IP_London #VisitingProfessor #Urology #Innovation

Post attachment
Advanced Prostate Cancer Consensus Conference avatar
⟳ Fabrice Lucien, PhD retweeted
Advanced Prostate Cancer Consensus Conference@APCCC_Lugano·May 13

Biochemical Recurrence Irradiation or Observation (BRIO) in patients with prostate cancer: protocol for a randomised control trial (Study Protocol) bjui-journals.onlinelibrary.… BRIO is a prospective randomized trial evaluating whether immediate salvage radiotherapy (SRT) ☢️ improves outcomes versus observation with delayed image-guided treatment in men with biochemical recurrence after radical prostatectomy who have negative mpMRI and PSMA-PET/CT imaging. The study will enroll 312 patients with PSA 🧪 0.2–1.5 ng/mL and assess distant recurrence-free survival, quality of life, adverse effects, and biomarker development to clarify optimal management of imaging-negative recurrent #ProstateCancer after surgery overall @DrStish @JakeOrmeMDPhD @vidit_sharma_ @JackAndrewsMD @flscientist @OncoAlert 🚨 @Silke_Gillessen @AOmlin @weoncologists

Post attachment